Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808594 | 0.89 | PDE4A (0.62) | PDE4APDE4BPDE4DPDE4CTNF | |
| Cdc-801 SCHEMBL29360102 | 0.82 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CTNF | |
| Cdc-801 SCHEMBL9977552 | 0.82 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CTNF | |
| Cdc-801 SCHEMBL185853 | 0.82 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CTNF | |
| SCHEMBL4637138 | 0.81 | PDE4A (0.98) | PDE4APDE4BPDE4DPDE4CTNF | |
| SCHEMBL7359135 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7099179 | 0.81 | PDE4B (0.53) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL3218695 | 0.80 | PDE4B (0.50) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL3218687 | 0.78 | PDE4B (0.49) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL9977546 | 0.78 | PDE4A (0.80) | PDE4APDE4BPDE4DPDE4CTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | claimed |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | NYCOMED GMBH (DE) | 2006-07-06 | — | — | US | claimed |
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | ALTANA PHARMA AG (DE) | 2006-04-13 | — | — | US | claimed |
| EP-1587512-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA Pharma AG (DE) | 2005-10-26 | — | — | EP | claimed |
| EP-1567136-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA Pharma AG (DE) | 2005-08-31 | — | — | EP | claimed |
| US-20050014762-A1 | Combination | NYCOMED GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| EP-1482938-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA Pharma AG (DE) | 2004-12-08 | — | — | EP | claimed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004062671-A2 | PDE4 INHIBITORS FOR THE TREATMENT OF NEOPLASMS OF LYMPHOID CELLS | ALTANA PHARMA AG (DE) | 2004-07-29 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | claimed |
| WO-2003074055-A1 | PHARMACEUTICAL COMPOSITION OF A PDE4 OR A PDE3/4 INHIBITOR AND A HISTAMINE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-09-12 | — | — | WO | claimed |
| US-20030092706-A1 | Combination | NYCOMED GMBH (DE) | 2003-05-15 | — | — | US | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079540-A1 | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | PDE4A, PDE12, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4D 8/4885 |
| US-20060148804-A1 | Pde4 inhibitors for the treatment of neoplasms of lymphoid cells | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4D 4/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | PDE4A 357/4885PDE4B 399/4885PDE4D 549/4885 |
| US-20050014762-A1 | Combination | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4D 10/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | PDE4A 357/4885PDE4B 399/4885PDE4D 549/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | PDE4A 102/4885PDE4B 180/4885PDE4D 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.